Document registry — page 14
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Comment-period correspondent, peptide chemistry. Independent analytical consultancy
30 Jul 2026 -
Submitted-evidence contributor, clinical pharmacology. ISO/IEC 17025-accredited contract testing laboratory
30 Jul 2026 -
Comment-period correspondent, medicines information. Academic peptide-chemistry group
30 Jul 2026 -
Comment-period correspondent, endocrinology. Health-technology assessment agency
30 Jul 2026 -
Submitted-evidence contributor, toxicology. Independent analytical consultancy
30 Jul 2026 -
External reviewer, hepatology. Academic sports-medicine and anti-doping laboratory
30 Jul 2026 -
Comment-period correspondent, pharmacy practice. University teaching hospital, department of endocrinology
30 Jul 2026 -
Submitted-evidence contributor, regulatory science. Academic peptide-chemistry group
30 Jul 2026 -
Specialist adviser, clinical biochemistry. ISO/IEC 17025-accredited contract testing laboratory
30 Jul 2026 -
Comment-period correspondent, toxicology. National medicines information service
30 Jul 2026 -
Submitted-evidence contributor, mass spectrometry. Regional hospital pharmacy department
30 Jul 2026 -
External reviewer, nephrology. University department of public health
30 Jul 2026 -
External reviewer, clinical pharmacology. Public-sector clinical trials unit
30 Jul 2026 -
External reviewer, cardiovascular outcomes. Independent analytical consultancy
30 Jul 2026 -
External reviewer, paediatric endocrinology. Independent evidence-synthesis consultancy
30 Jul 2026 -
Comment-period correspondent, public health. Metabolic medicine service, tertiary centre
30 Jul 2026 -
Comment-period correspondent, evidence synthesis. Community pharmacy practice, doctoral candidate
30 Jul 2026 -
Specialist adviser, endocrinology. University department of pharmacy practice
30 Jul 2026 -
External reviewer, cardiovascular outcomes. Sleep and respiratory medicine service
30 Jul 2026 -
Comment-period correspondent, pharmaceutics. Academic mass-spectrometry core facility
30 Jul 2026 -
External reviewer, public health. Metabolic medicine service, tertiary centre
30 Jul 2026 -
Comment-period correspondent, paediatric endocrinology. University department of pharmacy practice
30 Jul 2026 -
Submitted-evidence contributor, microbiological quality. National medicines information service
30 Jul 2026 -
External reviewer, clinical biochemistry. Public-sector clinical trials unit
30 Jul 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Exenatide compared with the comparator used in its contributing trials on the anchor…
High28 Jul 2026 -
Consultation on the draft of CEI-MS-20, which specifies the performance a determination must achieve for stability and states what the resulting figure does not…
26 Jul 2026 -
Interventions proposed to modify rate of biological ageing, assessed by composite biomarker clocks, functional measures, or mortality.
25 Jul 2026 -
Peptides, SARMs, injectable oils and raw materials.
23 Jul 2026 -
Consultation on the draft scoping review of change in lean mass during pharmacologically induced weight reduction. The review is scoping rather than an intervention…
21 Jul 2026 -
Consultation on the draft monograph for CJC-1295, which the assessment committee released for public comment before ratification. The draft grades the compound's…
21 Jul 2026 -
Consultation on the draft of CEI-MS-07, which specifies the performance a determination must achieve for physical quality and states what the resulting figure does not…
21 Jul 2026 -
Oral non-peptide GLP-1 receptor agonist. Small-molecule GLP-1 receptor agonism with a short half-life requiring twice-daily administration. The Institute includes this monograph specifically…
Low20 Jul 2026 -
Peptides, SARMs, injectable oils and raw materials. 350+ catalogue lines.
20 Jul 2026 -
Consultation on the draft of this analytical evidence review, which registers the question: How much does a reported chromatographic purity figure vary with the method…
19 Jul 2026 -
Phase 1 ascending dose, phase 1 study of Survodutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low19 Jul 2026 -
In the population defined for obesity and overweight in adults, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the…
Moderate18 Jul 2026 -
Consultation on the draft monograph for MOTS-c, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
15 Jul 2026 -
Amylin analogue, short-acting. Pramlintide reproduces the postprandial actions of endogenous amylin, which is deficient in insulin-deficient diabetes: it slows gastric emptying…
Moderate15 Jul 2026 -
Thymic peptide extract of undefined composition. Thymalin is a fractionated calf-thymus extract registered in the Russian Federation as an immunomodulator. Because its composition is not defined, no…
Very low15 Jul 2026 -
Consultation on the draft of this intervention review, which registers the question: What randomised evidence supports mitochondria-targeted peptides in primary…
14 Jul 2026
page 14 of 41